SCHEMBL1869664

SCHEMBL1869664

Cn1nc(C(C)(C)C)cc1C(=O)NNC(=O)c1ccc(Cl)s1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.49
KDM4E B2RXH2 3/20 0.49
HTT P42858 2/20 0.49
HSD17B10 Q99714 2/20 0.49
RAB9A P51151 2/20 0.49
NPC1 O15118 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
GRN P28799 1/20 0.49
SORT1 Q99523 1/20 0.49
MAPK1 P28482 3/20 0.45
KMT2A Q03164 1/20 0.45
ALDH1A1 P00352 2/20 0.44
HPGD P15428 1/20 0.44
ALOX12 P18054 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
GALR3 O60755 1/20 0.43
AAK1 Q2M2I8 1/20 0.43
EPHX2 P34913 1/20 0.42
BRAF P15056 2/20 0.42
MAPK13 O15264 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18196052 0.86 KDM4E (0.50) LMNAKDM4EHTTHSD17B10RAB9A
SCHEMBL1865416 0.79 RAB9A (0.52) LMNAKDM4EHTTHSD17B10RAB9A
SCHEMBL7985728 0.72 KDM4E (0.67) LMNAKDM4EHTTHSD17B10RAB9A
SCHEMBL1903709 0.72 MAPT (0.68) LMNAKDM4EHSD17B10RAB9ANPC1
SCHEMBL350954 0.71 KDM4E (0.65) LMNAKDM4EHTTRAB9AGRN
SCHEMBL1897017 0.70 BRAF (0.58) KDM4ERAB9ANPSR1GRNSORT1
SCHEMBL27572930 0.69 F2 (0.52) LMNAKDM4EHTTRAB9ANPC1
SCHEMBL350765 0.69 GRN (0.71) LMNAKDM4ERAB9AGRNSORT1
SCHEMBL13753933 0.69 KDM4E (0.61) LMNAKDM4EHTTHSD17B10RAB9A
Hydrochloric Acid SCHEMBL6312227 0.69 KDM4E (0.56) LMNAKDM4EHTTHSD17B10RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10751495-B2 Patient interface KONINKLIJKE PHILIPS N.V. (NL) 2020-08-25 US disclosed
US-20110105597-A1 Modulation of pathogenicity QUONOVA, LLC 2011-05-05 US disclosed
US-20110105597-A1 Modulation of pathogenicity QUONOVA, LLC 2011-05-05 US disclosed
US-20100280036-A1 Modulation of Pathogenicity QUONOVA, LLC 2010-11-04 US disclosed
US-20100280036-A1 Modulation of Pathogenicity QUONOVA, LLC 2010-11-04 US disclosed
US-20100280036-A1 Modulation of Pathogenicity QUONOVA, LLC 2010-11-04 US disclosed
EP-1478364-B1 SELECTIVE ANTIBACTERIAL AGENTS QUONOVA LLC (US) 2009-09-16 EP disclosed
US-20090076012-A1 Modulation of pathogenicity QUONOVA, LLC 2009-03-19 US disclosed
US-20090076012-A1 Modulation of pathogenicity QUONOVA, LLC 2009-03-19 US disclosed
US-20090076012-A1 Modulation of pathogenicity QUONOVA, LLC 2009-03-19 US disclosed
US-20080182878-A1 Modulation of pathogenicity QUONOVA, LLC 2008-07-31 US disclosed
US-20080176938-A1 Modulation of pathogenicity QUONOVA, LLC 2008-07-24 US disclosed
US-20080176938-A1 Modulation of pathogenicity QUONOVA, LLC 2008-07-24 US disclosed
US-20080176938-A1 Modulation of pathogenicity QUONOVA, LLC 2008-07-24 US disclosed
US-7335779-B2 Modulation of pathogenicity QUONOVA, LLC (US) 2008-02-26 US disclosed
US-7335779-B2 Modulation of pathogenicity QUONOVA, LLC (US) 2008-02-26 US disclosed
US-7335779-B2 Modulation of pathogenicity QUONOVA, LLC (US) 2008-02-26 US disclosed
EP-1478364-A2 SELECTIVE ANTIBACTERIAL AGENTS 4SC AG (DE) 2004-11-24 EP disclosed
US-20040063765-A1 Modulation of pathogenicity 4 SC AG (DE) 2004-04-01 US disclosed
WO-2003039549-A2 SELECTIVE ANTIBACTERIAL AGENTS 4SC AG (DE) 2003-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076012-A1 Modulation of pathogenicity NR4A1, NR4A2, NR4A3 LMNA 3658/4885KDM4E 3680/4885HTT 4218/4885
US-20110105597-A1 Modulation of pathogenicity NR4A1, NR4A2, NR4A3 LMNA 3684/4885KDM4E 3715/4885HTT 4231/4885
US-20100280036-A1 Modulation of Pathogenicity NR4A1, NR4A2, NR4A3 LMNA 3684/4885KDM4E 3715/4885HTT 4231/4885
US-20080182878-A1 Modulation of pathogenicity NR4A1, NR4A2, MSR1 LMNA 3656/4885KDM4E 3712/4885HTT 4229/4885
US-20080176938-A1 Modulation of pathogenicity NR4A1, NR4A2, NR4A3 LMNA 3839/4885KDM4E 3704/4885HTT 4216/4885
US-20040063765-A1 Modulation of pathogenicity NR1H4, NR4A1, MSR1 LMNA 2977/4885KDM4E 3783/4885HTT 4502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.